We believe that biotechnology can maximize this potential by providing more sophisticated ways to attack disease. Amgen was among the first companies to develop therapeutic proteins, which can replace or augment beneficial human proteins, and monoclonal antibodies, which can strike disease targets with enhanced precision. Our scientists have also engineered new types of medicines, such as peptibodies, and our pipeline features other entirely novel treatment modalities.
This commitment to therapeutic innovation is accompanied by a strong presence on the frontiers of human biology. Advances in human genetics are shedding new light on the molecular roots of disease. Amgen’s goal is to turn these insights into new and highly differentiated therapies. As a science-driven company, we pursue this goal through substantial internal investments, and we also leverage external innovation to complement our core capabilities.
The success of Amgen R&D can be seen in our product portfolio, which includes novel therapies for hard-to-treat diseases. These therapies have been used to treat more than 25 million patients worldwide with diseases that include cancer, kidney failure, blood and autoimmune disorders, and bone diseases. We are building on these successes with a drug pipeline that aims to help patients with conditions such as heart disease, schizophrenia, and migraine.